Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
bioAffinity Technologies Inc
BIAF
Alternate Symbol(s):
BIAFW
Healthcare
Diagnostics & Research
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze...
cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:BIAF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 28, 2025 8:01am
New Press Release - bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
Australian patent strengthens global patent portfolio bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company’s noninvasive test for lung cancer, today announced that the Australian Patent Office (IP...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 20, 2025 8:00am
New Press Release - bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
Visit the CyPath® Lung team at Booth #2242 October 19-22 bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced it will present research at CHEST 2025, the annual meeting of the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 16, 2025 8:00am
New Press Release - bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
U.S. award protects AI-built platform and adds to growing international patent portfolio bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 15, 2025 8:00am
New Press Release - bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced that it has received a written notice from The Nasdaq Stock Market...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 09, 2025 2:01pm
New Press Release - WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 09, 2025 1:00pm
New Press Release - bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the previously announced definitive agreements for the purchase and sale of 720,000 shares of common stock...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 08, 2025 4:16pm
New Press Release - WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 08, 2025 3:45pm
New Press Release - bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0...
read article.
(235)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Oct 08, 2025 8:14am
Buy buddy buy.
Otherwise it will be FOMO time for you fellas out there today,so good luck to all of you
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 07, 2025 8:00am
New Press Release - bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 30, 2025 12:45pm
New Press Release - WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
JERSEY CITY, N.J., Sept. 30, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) a biotechnology company focused on the need for noninvasive tests for...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 30, 2025 12:15pm
New Press Release - bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its previously announced public offering of securities as described below for aggregate gross proceeds to...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 29, 2025 6:01pm
New Press Release - WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
JERSEY CITY, N.J., Sept. 29, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) a biotechnology company focused on the need for noninvasive tests for...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 29, 2025 3:51pm
New Press Release - bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a public offering of securities as described below for aggregate gross proceeds to the Company of $4.8...
read article.
(476)
•••
Iseneschal
X
Comment by
Iseneschal
on Sep 29, 2025 10:23am
RE:BIAF....take wild guess?
BIAF ....N.L.O.D $4.04..... Now what???
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Environmental technology company enters a new strategic phase focused on scale and profitability